P1048: MYF3001: A RANDOMIZED OPEN LABEL, PHASE 3 STUDY TO EVALUATE IMETELSTAT VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS REFRACTORY TO JANUS KINASE INHIBITOR. (23rd June 2022)

Record Type:: Journal Article
Title:: P1048: MYF3001: A RANDOMIZED OPEN LABEL, PHASE 3 STUDY TO EVALUATE IMETELSTAT VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS REFRACTORY TO JANUS KINASE INHIBITOR. (23rd June 2022)
Main Title:: P1048: MYF3001: A RANDOMIZED OPEN LABEL, PHASE 3 STUDY TO EVALUATE IMETELSTAT VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS REFRACTORY TO JANUS KINASE INHIBITOR
Authors:: Mascarenhas, J.
Harrison, C. N.
Kiladjian, J.-J.
Komrokji, R. S.
Koschmieder, S.
Vannucchi, A. M.
Berry, T.
Redding, D.
Sherman, L.
Dougherty, S.
Peng, L.
Sun, L.
Huang, F.
Wan, Y.
Feller, F. M.
Rizo, A.
Verstovsek, S.
Abstract:
Is Part Of:: HemaSphere. Volume 6(2022)Supplement 3
Journal:: HemaSphere
Issue:: Volume 6(2022)Supplement 3
Issue Display:: Volume 6, Issue 3 (2022)
Year:: 2022
Volume:: 6
Issue:: 3
Issue Sort Value:: 2022-0006-0003-0000
Page Start:: 938
Page End:: 939
Publication Date:: 2022-06-23
Subjects:: Hematology -- Periodicals
616.15005
Journal URLs:: https://journals.lww.com/hemasphere/pages/default.aspx ↗
http://journals.lww.com/pages/default.aspx ↗
DOI:: 10.1097/01.HS9.0000847060.14020.7d ↗
Languages:: English
ISSNs:: 2572-9241
Deposit Type:: Legaldeposit
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:: British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store
Ingest File:: 22735.xml